期刊
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
卷 320, 期 5, 页码 H1999-H2010出版社
AMER PHYSIOLOGICAL SOC
DOI: 10.1152/ajpheart.00951.2020
关键词
bioengineering; comorbidities; extracellular vesicles; myocardial ischemia; stem cells
资金
- National Heart, Lung, and Blood Institute [1R01HL133624, R01HL128831, R01HL46716]
Cardiovascular disease is the leading cause of death globally. Current treatment options are limited, and stem-cell-derived extracellular vesicles (EVs) therapy shows promise but also faces several challenges.
Cardiovascular disease (CVD) is the leading cause of death globally. Current treatment options include lifestyle changes, medication, and surgical intervention. However, many patients are unsuitable candidates for surgeries due to comorbidities, diffuse coronary artery disease, or advanced stages of heart failure. The search for new treatment options has recently transitioned from cell-based therapies to stem-cell-derived extracellular vesicles (EVs). A number of challenges remain in the EV field, including the effect of comorbidities, characterization, and delivery. However, recent revolutionary developments and insight into the potential of personalizing EV contents by bioengineering methods to alter specific signaling pathways in the ischemic myocardium hold promise. Here, we discuss the past limitations of cell-based therapies and recent EV studies involving in vivo, in vitro, and omics, and future challenges and opportunities in EV-based treatments in CVD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据